| For: | Ganzetti G, Campanati A, Offidani A. Non-alcoholic fatty liver disease and psoriasis: So far, so near. World J Hepatol 2015; 7(3): 315-326 [PMID: 25848461 DOI: 10.4254/wjh.v7.i3.315] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v7/i3/315.htm |
| Number | Citing Articles |
| 1 |
R.B. Prussick, L. Miele. Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden?. British Journal of Dermatology 2018; 179(1) doi: 10.1111/bjd.16239
|
| 2 |
Chunwei Cheng, Jun Tan, Wei Qian, Lei Zhang, Xiaohua Hou. Gut inflammation exacerbates hepatic injury in the high-fat diet induced NAFLD mouse: Attention to the gut-vascular barrier dysfunction. Life Sciences 2018; 209 doi: 10.1016/j.lfs.2018.08.017
|
| 3 |
J.M. Carrascosa, C. Bonanad, E. Dauden, R. Botella, A. Olveira-Martín. Psoriasis e hígado graso no alcohólico. Actas Dermo-Sifiliográficas 2017; 108(6) doi: 10.1016/j.ad.2016.12.017
|
| 4 |
M. A. Livzan, O. V. Gaus, I. N. Ekimov. Non-alcoholic fatty liver disease and psoriasis: mechanisms of comorbidity and approaches to therapy. Meditsinskiy sovet = Medical Council 2024; (2) doi: 10.21518/ms2024-045
|
| 5 |
Yuhei Aotani, Yuta Kumagai, Masanobu Kameda, Kenji Wada, Toshiyuki Matsunaka, Hiroyasu Morikawa, Hiromichi Horinaka. Improvement of a combined ultrasonic probe used in ultrasonic velocity-change method for evaluation of fat content. Japanese Journal of Applied Physics 2018; 57(7S1) doi: 10.7567/JJAP.57.07LF18
|
| 6 |
Anna Baran, Julia Nowowiejska, Julia Parzych, Justyna Magdalena Hermanowicz, Beata Sieklucka, Dariusz Pawlak, Iwona Flisiak. Plasma Galectin-4 and Charcot-Leyden Crystal Protein/Galectin-10 as Emerging Biomarkers of Metabolically Induced Inflammation in Patients with Psoriasis. International Journal of Molecular Sciences 2025; 26(21) doi: 10.3390/ijms262110339
|
| 7 |
Oriana Simonetti, Giulio Rizzetto, Elisa Molinelli, Federico Diotallevi, Giulia Radi, Oscar Cirioni, Marcello Mario D’Errico, Annamaria Offidani. Safety and Efficacy of Vaccines during COVID-19 Pandemic in Patients Treated with Biological Drugs in a Dermatological Setting. Healthcare 2021; 9(4) doi: 10.3390/healthcare9040401
|
| 8 |
Gwyneth Armijo-Borjon, Alessandra Irais Miranda-Aguirre, Arnulfo Garza-Silva, Iván Francisco Fernández-Chau, Miguel Ángel Sanz-Sánchez, Arnulfo González-Cantú, Maria Elena Romero-Ibarguengoitia. Biologic therapy for psoriasis is associated with the development of metabolic dysfunction-associated steatotic liver disease (MASLD). A study on the association of cardiometabolic conditions with psoriasis treatment. Archives of Dermatological Research 2025; 317(1) doi: 10.1007/s00403-024-03688-5
|
| 9 |
Gyongyi Szabo, Timea Csak. Role of MicroRNAs in NAFLD/NASH. Digestive Diseases and Sciences 2016; 61(5) doi: 10.1007/s10620-015-4002-4
|
| 10 |
J.M. Carrascosa, C. Bonanad, E. Dauden, R. Botella, A. Olveira-Martín. Psoriasis and Nonalcoholic Fatty Liver Disease. Actas Dermo-Sifiliográficas (English Edition) 2017; 108(6) doi: 10.1016/j.adengl.2017.05.017
|
| 11 |
Xin Sun, Yan Zhang, Meilin Xie. The role of peroxisome proliferator-activated receptor in the treatment of non-alcoholic fatty liver disease. Acta Pharmaceutica 2017; 67(1) doi: 10.1515/acph-2017-0007
|
| 12 |
Aine Kelly, Caitriona Ryan. Psoriasis: Beyond the Skin. European Medical Journal 2018; doi: 10.33590/emj/10311854
|
| 13 |
L. B. Lazebnik, S. V. Turkina. NAFLD Associated Comorbidity. Experimental and Clinical Gastroenterology 2021; (10) doi: 10.31146/1682-8658-ecg-194-10-5-13
|
| 14 |
Lisa B. VanWagner, Mary E. Rinella. Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. Current Hepatology Reports 2016; 15(2) doi: 10.1007/s11901-016-0295-9
|
| 15 |
Antonio Benedetti, Anna Campanati, Emanuela Martina, Oriana Simonetti, Emanuele Bendia, Antonio Di Sario, Luca Maroni, Marco Marzioni, Irene Pierantonelli, Paola Sassaroli, Laura Schiadà, Gianluca Svegliati-Baroni, Giuseppe Tarantino, Annamaria Offidani. The First Outstanding 50 Years of “Università Politecnica delle Marche”. 2020; doi: 10.1007/978-3-030-33832-9_16
|
| 16 |
Pasinee Rongngern, Leena Chularojanamontri, Chanisada Wongpraparut, Narumol Silpa-Archa, Watcharasak Chotiyaputta, Ananya Pongpaibul, Phunchai Charatcharoenwitthaya. Diagnostic performance of transient elastography for detection of methotrexate-induced liver injury using Roenigk classification in Asian patients with psoriasis: a retrospective study. Archives of Dermatological Research 2017; 309(5) doi: 10.1007/s00403-017-1733-4
|
| 17 |
Sylvia Zanesco, Wendy Hall, Rachel Gibson, Christopher Griffiths, Thiviyani Maruthappu. Approaches to nutrition intervention in plaque psoriasis, a multi‐system inflammatory disease—The Diet and Psoriasis Project (DIEPP). Nutrition Bulletin 2022; 47(4) doi: 10.1111/nbu.12580
|
| 18 |
Ali Ismail, Ahmad Saad, Ramy Draz. Effect of low-calorie diet on psoriasis severity index, triglycerides, liver enzymes, and quality of life in psoriatic patients with non-alcoholic fatty liver disease. Rheumatology 2023; 61(2) doi: 10.5114/reum/162995
|
| 19 |
Stefano Ballestri, Alessandro Mantovani, Fabio Nascimbeni, Simonetta Lugari, Amedeo Lonardo. Extra-Hepatic Manifestations and Complications of Nonalcoholic Fatty Liver Disease. Future Medicinal Chemistry 2019; 11(16) doi: 10.4155/fmc-2019-0003
|
| 20 |
Ivana Mikolasevic, Sandra Milic, Tamara Turk Wensveen, Ivana Grgic, Ivan Jakopcic, Davor Stimac, Felix Wensveen, Lidija Orlic. Nonalcoholic fatty liver disease - A multisystem disease?. World Journal of Gastroenterology 2016; 22(43): 9488-9505 doi: 10.3748/wjg.v22.i43.9488
|
| 21 |
Talat Bessissow, Ngoc Han Le, Kathleen Rollet, Waqqas Afif, Alain Bitton, Giada Sebastiani. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2016; 22(8) doi: 10.1097/MIB.0000000000000832
|
| 22 |
M. A. Livzan, O. V. Gaus, N. A. Nikolaev, T. S. Krolevetz. NAFLD: comorbidity and associated diseases. Experimental and Clinical Gastroenterology 2020; 1(10) doi: 10.31146/1682-8658-ecg-170-10-57-65
|
| 23 |
Valerio Rosato, Mario Masarone, Marcello Dallio, Alessandro Federico, Andrea Aglitti, Marcello Persico. NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome. International Journal of Environmental Research and Public Health 2019; 16(18) doi: 10.3390/ijerph16183415
|
| 24 |
Andrew A. Li, Aijaz Ahmed, Donghee Kim. Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. Gut and Liver 2020; 14(2) doi: 10.5009/gnl19069
|
| 25 |
Mercedes Perez-Carreras, Begoña Casis-Herce, Raquel Rivera, Inmaculada Fernandez, Pilar Martinez-Montiel, Victoria Villena. Non-alcoholic fatty liver disease in patients with intestinal, pulmonary or skin diseases: Inflammatory cross-talk that needs a multidisciplinary approach. World Journal of Gastroenterology 2021; 27(41): 7113-7124 doi: 10.3748/wjg.v27.i41.7113
|
| 26 |
Naif O. Al-Harbi, Ahmed Nadeem, Mohammed M. Al-Harbi, Khairy M.A. Zoheir, Mushtaq A. Ansari, Ahmed M. El-Sherbeeny, Khalid M. Alanazi, Moureq R. Alotaibi, Sheikh F. Ahmad. Psoriatic inflammation causes hepatic inflammation with concomitant dysregulation in hepatic metabolism via IL-17A/IL-17 receptor signaling in a murine model. Immunobiology 2017; 222(2) doi: 10.1016/j.imbio.2016.10.013
|
| 27 |
Maria Chondronikola, Souvik Sarkar. Total-body PET Imaging. PET Clinics 2021; 16(1) doi: 10.1016/j.cpet.2020.09.001
|
| 28 |
O. B. Nemchaninova, E. Yu. Sklyanova, S. G. Lykova, E. N. Makhnovets, O. N. Pozdnyakova, T. B. Reshetnikova, A. A. Khryanin. Comorbidity: non-alcoholic fatty liver disease and psoriasis. Experimental and Clinical Gastroenterology 2021; (10) doi: 10.31146/1682-8658-ecg-194-10-55-60
|
| 29 |
Emma Coussens, Lynda Grine, Jessica Bostoen, Herman Mielants, Jo Lambert. Analysis of telomere length as predictive marker in psoriasis for comorbidities. Experimental Dermatology 2016; 25(5) doi: 10.1111/exd.12959
|
| 30 |
A. Campanati, D. Benfaremo, M. M. Luchetti, G. Ganzetti, A. Gabrielli, A. Offidani. Certolizumab pegol for the treatment of psoriasis. Expert Opinion on Biological Therapy 2017; 17(3) doi: 10.1080/14712598.2017.1283401
|
| 31 |
Deepak MW Balak, Stefano Piaserico, Ismail Kasujee. Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients with Psoriasis: A Review of the Hepatic Effects of Systemic Therapies. Psoriasis: Targets and Therapy 2021; doi: 10.2147/PTT.S342911
|
| 32 |
Dan Ilkovitch, Laura K. Ferris. Myeloid-derived suppressor cells are elevated in patients with psoriasis and produce various molecules. Molecular Medicine Reports 2016; 14(4) doi: 10.3892/mmr.2016.5685
|
| 33 |
Xiaonan Wang, Yuting Jiao, Shengwei Zhou, Yaqi Fang, Huantong Duan, Zhi Yang. Ultrasound-guided attenuation parameter for hepatic steatosis quantification in psoriasis: a retrospective cohort study: Quantitatively evaluate of hepatic steatosis. Medicine 2025; 104(52) doi: 10.1097/MD.0000000000046896
|
| 34 |
Che-Yung Chao, Robert Battat, Alex Al Khoury, Sophie Restellini, Giada Sebastiani, Talat Bessissow. Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article. World Journal of Gastroenterology 2016; 22(34): 7727-7734 doi: 10.3748/wjg.v22.i34.7727
|
| 35 |
Anna Campanati, Elisa Molinelli, Valerio Brisigotti, Donatella Brancorsini, Ivan Bobyr, Federico Diotallevi, Giulia Radi, Annamaria Offidani. Treatment of Moderate-to-Severe Psoriasis in the Presence of Kaposi’s Varicelliform Eruption. Case Reports in Dermatology 2019; 11(Suppl. 1) doi: 10.1159/000501992
|
| 36 |
Giulia Radi, Anna Campanati, Federico Diotallevi, Giulio Rizzetto, Emanuela Martina, Ivan Bobyr, Melania Giannoni, Annamaria Offidani. Long‐term efficacy and safety of apremilast in the treatment of plaques psoriasis: A real‐world, single‐center experience. Dermatologic Therapy 2021; 34(6) doi: 10.1111/dth.15179
|
| 37 |
L. S. Kruglova, N. S. Rudneva, G. G. Egoyan. Issues of use of hepatoprotectors in psoriasis: Indications and effectiveness. Medical alphabet 2022; (8) doi: 10.33667/2078-5631-2022-8-61-66
|
| 38 |
Jie HU, YaQiong Shao, Cheng Gui, Yihui Xiao, Lixia Li, Zheng Li. Prevalence and risk of nonalcoholic fatty liver disease among adult psoriatic patients: A systematic review, meta-analysis, and trial sequential analysis. Medicine 2024; 103(18) doi: 10.1097/MD.0000000000038007
|
| 39 |
Mónica Munera-Campos, Jaime Vilar-Alejo, Raquel Rivera, Jose-Manuel Carrascosa, Esteban Daudén, Enrique Herrera-Acosta, Antonio Sahuquillo-Torralba, Francisco J. Gómez-García, Ofelia Baniandrés-Rodríguez, Pablo de la Cueva, Jose-Luis López-Estebaranz, Isabel Belinchón, Marta Ferran, Jose Riera-Monroig, Lourdes Rodriguez, Gregorio Carretero, Carmen García-Donoso, Ferran Ballescá, Mar Llamas-Velasco, Enrique Herrera-Ceballos, Conrad Pujol-Marco, Lula María Nieto-Benito, Diana P. Ruiz-Genao, Mercè Alsina, Miguel A. Descalzo, Ignacio García-Doval. The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry. Journal of Dermatological Treatment 2022; 33(4) doi: 10.1080/09546634.2021.1922572
|
| 40 |
Keisuke Sawada, Hak Chung, Samir Softic, Maria E. Moreno-Fernandez, Senad Divanovic. The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease. Cell Metabolism 2023; 35(11) doi: 10.1016/j.cmet.2023.10.009
|
| 41 |
Hanaa Mohamed Elhanon, Rabie B. Atallah, Ramadan M. Eldahshan, Saad El Deen Mohamed, Mohamed L. Elsaie. Non-alcoholic steatohepatitis incidence in patients with psoriasis vulgaris. Wiener Medizinische Wochenschrift 2025; 175(13-14) doi: 10.1007/s10354-025-01107-6
|
| 42 |
J. Albrecht, S. Gerdes. A new option on the horizon for the treatment of psoriasis: it is needed, but not at any price. British Journal of Dermatology 2016; 174(6) doi: 10.1111/bjd.14712
|
| 43 |
José María G. Ruiz de Morales, Lluís Puig, Esteban Daudén, Juan D. Cañete, José Luis Pablos, Antonio Olveira Martín, Carlos González Juanatey, Alfredo Adán, Xavier Montalbán, Natalia Borruel, Guillermo Ortí, Esther Holgado-Martín, Carolina García-Vidal, Cynthia Vizcaya-Morales, Víctor Martín-Vázquez, Miguel Ángel González-Gay. Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. Autoimmunity Reviews 2020; 19(1) doi: 10.1016/j.autrev.2019.102429
|
| 44 |
Anna Campanati, Matteo Paolinelli, Frederico Diotallevi, Emanuela Martina, Elisa Molinelli, Annamaria Offidani. Pharmacodynamics OF TNF α inhibitors for the treatment of psoriasis. Expert Opinion on Drug Metabolism & Toxicology 2019; 15(11) doi: 10.1080/17425255.2019.1681969
|
| 45 |
Yayoi Tada, Yukako Sugiura, Manami Kamishima, Yoshihito Tanaka, Hiroaki Tsuchiya, Junya Masuda, Keiichi Yamanaka. Safety and effectiveness of guselkumab in Japanese patients with psoriasis: 20‐week interim analysis of a postmarketing surveillance study. The Journal of Dermatology 2024; 51(6) doi: 10.1111/1346-8138.17255
|
| 46 |
Eveline De Brandt, Tom Hillary. Comorbid Psoriasis and Metabolic Syndrome: Clinical Implications and Optimal Management. Psoriasis: Targets and Therapy 2022; doi: 10.2147/PTT.S293107
|
| 47 |
Muzahir Hussain, Muhammad Umair Ijaz, Muhammad Ijaz Ahmad, Iftikhar Ali Khan, Syed Umar Farooq Bukhary, Waqar Khan, Sayed Hussain, Majid Suhail Hashmi, Chunbao Li. Gut inflammation exacerbates hepatic injury in C57BL/6J mice via gut-vascular barrier dysfunction with high-fat-incorporated meat protein diets. Food & Function 2020; 11(10) doi: 10.1039/D0FO02153A
|
| 48 |
Laura Huiban, Anca Trifan, Carol Stanciu. Essentials of Non-Alcoholic Fatty Liver Disease. 2023; doi: 10.1007/978-3-031-33548-8_20
|